RJA
BCLI

Raymond James & Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Raymond James & Associates’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-933
Closed -$1K – 4142
2021
Q3 		$1K Buy
+933
New +$49.1K ﹤0.01% 4097
2021
Q2 		– Sell
-1,667
Closed -$3K – 4098
2021
Q1 		$3K Buy
+1,667
New +$126K ﹤0.01% 3974

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Raymond James & Associates's BCLI Position: Q3 2024 in Review

Raymond James & Associates reduced its BRAINSTORM CELL THERAPUTC (BCLI) stake by 14% in Q3 2024, selling an estimated $5.07K and leaving 6,344 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3935.

Raymond James & Associates first reported a position in BCLI in Q3 2019 and has held it in 21 quarters since. The position peaked at $4.88M in Q3 2020. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • Raymond James & Associates held 6,344 shares of BRAINSTORM CELL THERAPUTC worth $21.9K as of Q3 2024.
  • Raymond James & Associates sold 1,075 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $5.07K.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3935 holding.
  • Raymond James & Associates first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2019 and has held it in 21 quarters since.
  • Raymond James & Associates's BRAINSTORM CELL THERAPUTC position peaked at $4.88M in Q3 2020.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.